Although TRAIL’s immunomodulatory effects could be attributed to a TRAIL/TRAIL-R–CCL2/CCR2 axis, it is important to note that TRAIL’s cancer secretome includes several other cytokines associated with tumor-supportive functions. The gene discussed is CCR2; the disease is neoplasm.